{
    "clinical_study": {
        "@rank": "41806", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group", 
                "arm_group_type": "Experimental", 
                "description": "Dignicap System"
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "No Intervention", 
                "description": "Concurrent age and chemotherapy matched control"
            }
        ], 
        "brief_summary": {
            "textblock": "The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will\n      be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant\n      chemotherapy regimens. The scalp cold cap will be applied at each chemotherapy cycle.  Hair\n      loss will be evaluated by patient self assessment of 5 standardized photographs taken prior\n      to each chemotherapy cycle.  A concurrent control group not using a cold cap will also be\n      evaluated."
        }, 
        "brief_title": "Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chemotherapy Adjuvant", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata", 
                "Breast Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients >/= 18 years of age\n\n          -  Documented diagnosis of stage I or II breast cancer\n\n          -  A planned course of chemotherapy in the adjuvant or neoadjuvant setting with curative\n             intent including one of the following regimens:\n\n               -  Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 x 4 - 6 cycles IV every 2 -\n                  3 weeks\n\n               -  Docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2  x 4 - 6 cycles IV every 3\n                  weeks\n\n               -  Paclitaxel 80 mg/m2 weekly IV x at least 12 weeks with or without IV trastuzumab\n\n               -  Paclitaxel 175 mg/m2 IV every 2 weeks x 4 - 6 cycles (without an anthracycline)\n\n               -  Paclitaxel weekly and carboplatin AUC 2 weekly or AUC 6  every 3 weeks IV x  4 -\n                  6 cycles and trastuzumab IV weekly or every 3 weeks\n\n               -  Docetaxel 75 mg/m2 and carboplatin AUC 6 IV every 3 weeks x 4 - 6 cycles and\n                  trastuzumab IV weekly or every 3 weeks\n\n               -  Targeted agents such as trastuzumab or lapatinib are allowed\n\n          -  Plan to complete chemotherapy within 6 months\n\n          -  At least two years out from the last chemotherapy causing hair loss with complete\n             recovery of hair\n\n          -  Karnofsky performance status >/= 80%\n\n          -  Willing and able to sign informed consent for protocol treatment\n\n          -  Willing to participate in study procedures including having photographs of the head\n             before the first cycle of chemotherapy and 1 month after the last chemotherapy\n\n          -  Willing to enroll in an extension protocol for follow up for 5 years following the\n             end of chemotherapy treatment\n\n        Exclusion Criteria:\n\n          -  Patients with female pattern baldness resembling picture I-3 or higher on the Savin\n             scale\n\n          -  Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with\n             associated hair loss\n\n          -  A history of whole brain radiation\n\n          -  Plans to use a chemotherapy regimen other than those specified in the inclusion\n             criteria. Specifically, patients receiving a regimen including both an anthracycline\n             and a taxane are not eligible for this trial (AC/T, EC/T, TAC, etc.)\n\n          -  Concurrent hormone therapy with chemotherapy.  Hormone therapy should be used as\n             indicated following completion of chemotherapy\n\n          -  Underlying clinically significant liver disease including active viral hepatitis with\n             abnormal liver function tests >1.5 times the upper limit of normal, including\n             alkaline phosphatase, AST, and total bilirubin. Patients with Gilbert\u00b4s disease\n             (elevated indirect bilirubin only) will be eligible for participation.\n\n          -  Clinically significant renal dysfunction defined as serum creatinine > upper limit of\n             normal.\n\n          -  A serious concurrent infection or medical illness which would jeopardize the ability\n             of the patient to complete the planned therapy and follow-up\n\n          -  A history of persistent grade 2 (or higher) alopecia induced by prior\n             chemotherapeutic regimens\n\n          -  Participation in any other clinical investigation or exposure to other\n             investigational agents, drugs, device or procedure that may cause hair loss\n\n          -  Intercurrent life-threatening malignancy\n\n          -  A history of cold agglutinin disease or cryoglobulinemia.\n\n          -  Evidence of untreated or poorly controlled hyper or hypothyroidism\n\n          -  A history of silicon allergy\n\n          -  American Society of Anesthesiologist Class \u22653"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831024", 
            "org_study_id": "DIG-001"
        }, 
        "intervention": {
            "arm_group_label": "Treatment Group", 
            "description": "The DigniCap\u2122 System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap\u2122), the neoprene outer cap (DigniTherm\u2122), and the liquid coolant (DigniCool). DIGNISTICK\u2122 is prepared to log data from a treatment when inserted in the slot. DIGNICARD\u2122 is a key card which has to be inserted in order to start a treatment.", 
            "intervention_name": "Dignicap System", 
            "intervention_type": "Device", 
            "other_name": "Cold cap"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cold cap", 
            "Scalp cooling", 
            "Chemotherapy induced alopecia", 
            "Breast cancer"
        ], 
        "lastchanged_date": "September 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "hrugo@medicine.ucsf.edu", 
                    "last_name": "Hope S. Rugo, MD", 
                    "phone": "415-353-7428"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "UCSF Helen Diller Family Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Hope S. Rugo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tec9002@med.cornell.edu", 
                    "last_name": "Tessa Cigler, MD", 
                    "phone": "617-821-0726"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weill Cornell Breast Center"
                }, 
                "investigator": {
                    "last_name": "Tessa Cigler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mgilyado@chpnet.org", 
                    "last_name": "Margarita Gilyadova, MD", 
                    "phone": "212-367-0181"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Beth Israel Medical Center, Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Paula Klein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "smelin@wakehealth.edu", 
                    "last_name": "Susan A. Melin, MD", 
                    "phone": "336-716-2839"
                }, 
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Wake Forest University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Susan A. Melin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Performance, Efficacy and Safety of the DigniCap\u2122 System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer", 
        "overall_contact": {
            "email": "gpark@targethealth.com", 
            "last_name": "Glen Park, PharmD", 
            "phone": "212-681-2100"
        }, 
        "overall_contact_backup": {
            "email": "ejurawicz@targethealth.com", 
            "last_name": "Eva Jurewicz", 
            "phone": "212-681-2100"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "5 standardized photographs will be evaluated by the patient using the Dean Scale for alopecia", 
            "measure": "Hair loss", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after last chemotherapy cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831024"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of patients who complete all planned cycles of chemotherapy do so using the DigniCap\u2122 System", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Every 2 to 4 weeks for up to 12 weeeks"
            }, 
            {
                "description": "spontaneous reporting by the patient or identified during physical examination", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Patient assessment using hair regrowth survey", 
                "measure": "Hair regrowth", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks after last chemotherapy"
            }, 
            {
                "description": "European Organization for Research and Treatment of Cancer-Quality of Life-BR23 questionnaire", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks after last chemotherapy cycle"
            }
        ], 
        "source": "Target Health Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Target Health Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}